Metabolic Syndrome in Patients with Non-alcoholic Fatty Liver Disease: A Community Based Cross-sectional study

Paudel, Mukesh S; Tiwari, Awadhesh; Mandal, Amrendra; Shrestha, B; Kafle, Paritosh; Chaulagai, Baikuntha; Kc, Sudhamshu

doi:10.7759/cureus.4099

Cited by 13 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed that SBP negatively and significantly correlated with CAP value. This finding is in contrast to the common dictum that CAP value, which is an indicator of steatosis, increases with the increase in the number of MetS components including HTN [29,30]. This disparity could be explained by the fact that most of the patients enrolled in this study were referred from general physicians for evaluation of fatty liver and were already getting treatment for comorbid conditions including HTN, and since more than half of the enrolled patients (51.2%) in this study were hypertensive and under medications, this could have generated a contradicting inference of correlation between NAFLD and blood pressure.…”

Section: Discussioncontrasting

confidence: 99%

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Shrestha¹,

Kc²,

Thapa³

et al. 2021

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundAssessment of nonalcoholic fatty liver disease (NAFLD) includes estimation of liver fat (steatosis).Controlled attenuation parameter (CAP) value obtained by FibroScan ® (Echosens, Paris, France) is an alternative to liver biopsy for diagnosing and estimating steatosis (S). This study aimed to estimate the liver fat by CAP in NAFLD patients. MethodsAn observational cross-sectional study was conducted at the Liver Unit of Bir Hospital, from January 2021 to May 2021 after ethical clearance from the Institutional Review Board of the National Academy of Medical Sciences. A convenient sampling method was used. Data were analyzed with descriptive and inferential statistics involving bivariate and multivariate analysis. ResultsA total of 127 NAFLD patients were enrolled. The mean (±SD) CAP value was 271.53 (±50.69) dB/m. Total cholesterol, triglyceride, and body mass index (BMI) correlated positively (p<0.05) while systolic blood pressure correlated negatively with CAP value (p=0.031). On multivariate analysis, patients with BMI ≥25 kg/m 2 were found 3.7 times more likely to have CAP ≥291 dB/m (S3, severe steatosis) than those with BMI <25 kg/m 2 (p=0.048, 95% CI 1.01, 13.50). The mean (±SD) CAP values were 276.19 (±49.93) and 246.60 (±48.50) dB/m among those with BMI ≥25 kg/m 2 and <25 kg/m 2 , respectively (p=0.016, using independent ttest). CAP steatosis grading correlated positively with both the ultrasound grading (p<0.001) and fibrosis grading by liver stiffness measurement (p=0.004). ConclusionIn this observational cross-sectional study of NAFLD patients, the mean (±SD) CAP value was 271.53 (±50.69) dB/m, which corresponds to moderate steatosis (S2). Obese NAFLD patients with ≥25 kg/m 2 were 3.7 times more likely to have severe steatosis (S3) than nonobese NAFLD patients with BMI <25 kg/m 2 .

show abstract

Section: Discussioncontrasting

confidence: 99%

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Shrestha¹,

Kc²,

Thapa³

et al. 2021

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…39 Numerous studies have shown that NAFLD is associated with obesity, insulin resistance, dyslipidemia and other metabolic disorders, but it also even precedes metabolic disorders. 40,41 In our study the NAFLD group had higher levels of BMI, blood pressure, FBG, FINS and HOMA-IR and higher prevalence of hyperlipidemia than those without NAFLD. These results show that there is a correlation between these variables and the presence of NAFLD.…”

Section: Discussionsupporting

confidence: 46%

Serum syndecan‐4 is associated with nonalcoholic fatty liver disease

Xia

Tang

et al. 2021

J of Digest Diseases

View full text Add to dashboard Cite

Objectives: The accelerated shedding of extracellular domains of syndecan-4 ( SDC4) is associated with central obesity and insulin resistance, while the association between serum SDC4 and nonalcoholic fatty liver disease (NAFLD) is unknown. We aimed to examine the association between SDC4 and NAFLD.Methods: Adults undergoing a health examination from 1 June 2019 to 31 December 2019 were enrolled. A diagnosis of NAFLD was made with an abdominal ultrasound. Logistic regression models and the receiver operating characteristic (ROC) curveswere used to evaluate the role of SDC4 in predicting NAFLD.Results: In total, 533 eligible participants were finally enrolled, among them 157 (29.46%) had NAFLD. The proportion of patients with NAFLD increased with the increasing quartiles of serum SDC4. With the increase of serum SDC4 levels, metabolic features including waist circumference, serum triglyceride, total cholesterol, fasting blood glucose, fasting insulin and homeostasis model assessment of insulin resistance were significantly increased. SDC4 was an independent factor for NAFLD (odds ratio 1.963, 95% confidence interval [CI] 1.628-2.367, P < 0.001). The area under the ROC curve of SDC4 for predicting NAFLD was 0.934 (95% CI 0.910-0.959). The optimal cut-off value was 6.575 ng/mL at Youden's index of 0.767. SDC4 had the highest diagnostic sensitivity (84.1%), positive predictive value (82.5%), negative predictive value (93.3%) and positive likelihood ratio (11.356) among all the variables.Conclusions: Elevated serum SDC4 level is associated with metabolic disorders and the prevalence of NAFLD among general population. Serum SDC4 may serve as a biomarker of NAFLD.

show abstract

“…Also, 90.0% and 33% NAFLD persons are found to be having at least one feature and all features of metabolic syndrome, respectively, thus increasing the risk of NAFLD to 4-11 times. Recently, a study done by Mukesh S. Paudel[ 13 ] in three different sites in and around Butwal sub metropolitan city of Rupandehi District Nepal concluded that 57.6% participants of non-alcoholic fatty liver were having metabolic syndrome and 91.4% participants of radiological fatty liver were having at least one component of metabolic syndrome.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of fatty liver in metabolic syndrome

Goyal

Arora

2020

J Family Med Prim Care

View full text Add to dashboard Cite

Background: In Western world, non-alcohlic fatty liver disease (NAFLD) is considered to be the commonest liver problem, and it is being recognised as a major cause of liver-related morbidity and mortality. As the prevalence of overweight/obesity and metabolic syndrome increases, NASH may become one of the more common causes of end stage liver disease and hepatocellular carcinoma. But much information is not available in this association. So an attempt has been made to correlate both. Aims: The aims of this study are: 1. to study the prevalence of non-alcoholic fatty liver in metabolic syndrome; and 2. to study the correlation between the non-alcoholic fatty liver and metabolic syndrome along with its individual components. Materials and Methods: The study was an observational and analytical study of patients attending OPD and indoor patients of the Department of Medicine, G.G.S. Medical College and Hospital Faridkot. In total, 100 patients diagnosed as metabolic syndrome according to the NCEP ATP III criteria were subjected to ultrasonography; age and sex matched 100 controls were also taken; and the relationship between metabolic syndrome and NAFLD was studied. Results: In total, 73% cases of metabolic syndrome according to NCEP ATPIII were having fatty liver, while in controls 38% persons were having fatty liver which is statistically significant. Conclusions: Fatty liver was found to be highly prevalent in metabolic syndrome, and the early detection of fatty liver can help in modifying the disease course and delaying more serious complications like cirrhosis of liver and hepatocellular carcinoma.

show abstract

Metabolic Syndrome in Patients with Non-alcoholic Fatty Liver Disease: A Community Based Cross-sectional study

Cited by 13 publications

References 16 publications

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Serum syndecan‐4 is associated with nonalcoholic fatty liver disease

Prevalence of fatty liver in metabolic syndrome

Contact Info

Product

Resources

About